Novel vaccine concept generates immune responses that could produce multiple types of HIV broadly neutralizing antibodies
NIH-funded animal model results will inform vaccine development in humans
2024-05-30
(Press-News.org) WHAT:
Using a combination of cutting-edge immunologic technologies, researchers have successfully stimulated animals’ immune systems to induce rare precursor B cells of a class of HIV broadly neutralizing antibodies (bNAbs). The findings, published today in Nature Immunology, are an encouraging, incremental step in developing a preventive HIV vaccine.
HIV is genetically diverse making the virus difficult to target with a vaccine, but bNAbs may overcome that hurdle because they bind to parts of the virus that remain constant even when it mutates. Germline targeting is an immune system-stimulating approach that guides naïve (precursor) B cells to develop into mature B cells that can produce bNAbs. A class of bNAbs called 10E8 is a priority for HIV vaccine development because it neutralizes a particularly broad range of HIV variants. The 10E8 bNAb binds to a conserved region of the glycoprotein gp41 on HIV’s surface involved in its entry into human immune cells. Designing an immunogen—a molecule used in a vaccine that elicits a specific immune system response—to stimulate production of 10E8 bNAbs has been challenging because that key region of gp41 is hidden in a recessed crevice on HIV’s surface. Prior vaccine immunogens have not generated bNAbs with the physical structure to reach and bind to gp41.
To address this challenge, the researchers engineered immunogens on nanoparticles that mimic the appearance of a specific part of gp41. They vaccinated rhesus macaque monkeys and mice with those immunogens and elicited specific responses from the 10E8 B cell precursors and induced antibodies that showed signs of maturing into bNAbs that could reach the hidden gp41 region. They observed similar responses when they used mRNA-encoded nanoparticles in mice. The researchers also found that the same immunogens produced B cells that could mature to produce an additional type of gp41-directed bNAb called LN01. Finally, their laboratory analysis of human blood samples found that 10E8-class bNAb precursors occurred naturally in people without HIV, and that their immunogens bound to and isolated naïve human B cells with 10E8-like features. Together these observations suggest that the promising immunization data from mice and macaques has the potential for translation to humans.
The research was conducted by the Scripps Consortium for HIV/AIDS Vaccine Development, one of two consortia supported by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). The research also was supported by collaborating partners including the Bill & Melinda Gates Foundation and other NIH Institutes and Offices. According to the authors, these findings support the development of the immunogens as the first part of a multi-step vaccine regimen for humans. Their work further supports research in developing a germline-targeting strategy for priming the immune system to elicit a bNAb called VRC01. This bNAb was discovered by NIAID researchers almost 15 years ago. The goal of this line of research is to develop an HIV vaccine that generates multiple classes of bNAbs to prevent HIV.
ARTICLE:
Schiffner et al. Vaccination induces broadly neutralizing antibody precursors to HIV gp41. Nature Immunology DOI: 10.1038/s41590-024-01833-w (2024).
WHO:
Angela Malaspina, program officer in NIAID’s Division of AIDS, is available to discuss this study.
CONTACT:
To schedule interviews, please contact NIAID News & Science Writing Branch, (301) 402-1663, niaidnews@niaid.nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.
NIH...Turning Discovery Into Health®
END
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2024-05-30
DARIEN, IL – A new study to be presented at the SLEEP 2024 annual meeting demonstrates that when individuals with obstructive sleep apnea use their positive airway pressure machine more regularly, it benefits their relationship with their partner.
Results show that greater adherence to PAP therapy was associated with higher levels of relationship satisfaction and lower levels of relationship conflict. Higher sleep efficiency among patients also was associated with higher levels of relationship satisfaction as reported by both the patient and their partner.
“Recognizing that sleep ...
2024-05-30
New research from the University of Lausanne reveals that both the excess and the deficiency of a single protein can lead to severe intellectual deficiencies. The discovery offers critical insights for early diagnosis of a rare developmental disorder.
A team of scientists led by Alexandre Reymond, an expert in human genetics at the Center for Integrative Genomics (CIG) and professor at the Faculty of Biology and Medicine (FBM) of the University of Lausanne (UNIL), presents a major step forward in the detection of a rare genetic disease. For ...
2024-05-30
Boston – Four teams of Dana-Farber Cancer Institute investigators have found that people experience discrimination and bias in different ways and in more realms of cancer care than previously understood. The findings, in different studies, suggest that oncology professionals and the systems they work in have more work to do to adapt to the realities of increasing diversity and inclusion, not only in the patient population but also in the oncology workforce. The research teams will present their findings at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. ASCO is the world’s largest clinical cancer ...
2024-05-30
ROCHESTER, Minnesota — Early detection improves treatment outcomes for endometrial and ovarian cancers, yet far too often women are diagnosed in advanced stages of these diseases. Unlike many other cancers, there are no standard screenings for early detection of endometrial and ovarian cancers. The incidence rate for endometrial cancer is expected to rise, driven by environmental factors, obesity and diabetes.
Marina Walther-Antonio, Ph.D., and colleagues at Mayo Clinic's Center for Individualized Medicine are on a mission to catch these cancers early.
Their research dives deep into the microbiome, a community of ...
2024-05-30
BIRMINGHAM, Ala. – RNA transcription is the genomic process in which a cell produces a duplicate of a gene’s DNA sequence.
In a study published in Nucleic Acids Research, University of Alabama at Birmingham Department of Chemistry Professor Jun Zhang, Ph.D., and his team reveal how the protein SRSF1 possesses the novel function of binding and unfolding complex RNA Guanine-quadruplexes.
Present in both DNA and RNA sequences, a G-quadruplex (GQ) is a structure of four guanine bases attached in a planar array. ...
2024-05-30
Osteoporosis, a condition characterized by porous and fragile bones, poses a significant threat to skeletal health. As the very framework of the human body, bones provide crucial structural support. When bone mass diminishes, it not only compromises this support but also impairs overall function, leading to a diminished quality of life. With the aging population experiencing a surge in osteoporosis cases, the strain on healthcare resources for long-term care is evident. Hence, there is a need to understand the mechanisms that contribute to osteoporosis and develop effective targeted therapies ...
2024-05-30
Transgender individuals often face unique challenges in aligning their physical bodies with their true gender identity. Among the various methods employed, gender-affirming hormone therapy (GAHT) stands as a vital means for transgender men to achieve physical changes in consonance with their gender identity. Navigating the complexities that come with gender transition, transgender individuals seek medical interventions to alleviate gender dysphoria and align their bodies with their gender identity.
For transgender men, testosterone therapy holds promise in inducing masculinizing effects such as increased muscle mass, cessation of ...
2024-05-30
Recommendations designed to reframe the evaluation of in vitro diagnostic tests have been published today by the Royal Statistical Society in its Series A journal.
The report, which will be submitted to the UK Covid-19 Inquiry, is intended to help prevent future scenarios in which IVDs are marketed widely, but later attract serious concerns about the standards applied to their evaluation.
The research was prompted by concerns about the standards applied to the evaluation of diagnostic tests during the Covid-19 pandemic – particularly lateral flow tests – however the recommendations cover all new tests, especially those ...
2024-05-30
Fossils found on the shoreline of Lake Kariba in Zimbabwe represent a completely new dinosaur species. This remarkable find, named Musankwa sanyatiensis, marks only the fourth dinosaur species named from Zimbabwe. The research detailing this significant discovery is set to be published in the prestigious journal Acta Palaeontologica Polonica. The study was conducted by an international team of scientists from the University of the Witwatersrand (Wits) in South Africa, the Natural History Museum of Zimbabwe, Stony Brook University in New York and was led by Prof Paul Barrett from the Natural History Museum ...
2024-05-30
BOSTON – A new study led by investigators from Mass General Cancer Center, a founding member of the Mass General Brigham healthcare system, reveals that statins—commonly used cholesterol-lowering drugs—may block a particular pathway involved in the development of cancer that results from chronic inflammation. The findings are published in Nature Communications.
“Chronic inflammation is a major cause of cancer worldwide,” said senior author Shawn Demehri, MD, PhD, a principal investigator at the Center for Cancer Immunology and Cutaneous Biology Research Center of Massachusetts General Hospital and an associate professor of Dermatology at ...
LAST 30 PRESS RELEASES:
[Press-News.org] Novel vaccine concept generates immune responses that could produce multiple types of HIV broadly neutralizing antibodies
NIH-funded animal model results will inform vaccine development in humans
